Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (378)	1/7/1999 11:45:00 AM
From: Rudy Saucillo	Read Replies (1) \| Respond to of 1073

Rick, It may be a good time to revisit DEPO. A decision by the FDA for DepoCyt could come any time now and, given the strong recommendation by the FDA advisory committee, I believe it's likely that DepoCyt will be approved. Also, we should hear news about the SkyePharma buyout of DepoTech in the near future. I'm anticipating a nice "bounce" on the upcoming FDA news. Rudy

To: scaram(o)uche who wrote (378)	1/7/1999 7:58:00 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 1073

Rick: I am curious why you added GENE to both portfolio, suddenly and with surprise? Was this move sort of momentum play, or with longer perspective? Cheap stock (from cash versus capitalization perspective), or programs and sound science is undervalued? For brief period of time in 97 I owned GENE, but substituted it with SQNA before ARRS merge. Genomic (PathoGenome) and anti-infective was my reasons at that time. I lost track on them for some time. Nonetheless, from bt universe dealing with antibiotic I didn't yet identified bt company which can convict me that they can successfully compete with pharma. I have from before MCDE and recently bought CBST, but this are not my true choice. Mostly results of the informed guess than love this company! :( GENE, with three programs (asthma, anti-infective and osteoporosis) is value player, but can they compete in crowded fields? Thanks for any thoughts. Miljenko